{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:47Z","timestamp":1790983127092,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04942-5","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:27:19Z","timestamp":1786937239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulatory compromise as a potential mechanism of fatal hepatic failure during long-term selpercatinib therapy: pharmacokinetic and clinical insights"],"prefix":"10.1007","volume":"96","author":[{"given":"Wataru","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Gando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Tomomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"3","key":"4942_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","volume":"15","author":"A Drilon","year":"2018","unstructured":"Drilon A, Hu ZI, Lai GGY et al (2018) Targeting RET-driven cancers: lessons from evolving therapies. Nat Rev Clin Oncol 15(3):151\u2013167. https:\/\/doi.org\/10.1038\/nrclinonc.2017.175","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"4942_CR2","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","volume":"29","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Velcheti V, Tuch BB et al (2018) Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 29(8):1869\u20131876. https:\/\/doi.org\/10.1093\/annonc\/mdy137","journal-title":"Ann Oncol"},{"issue":"9","key":"4942_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B et al (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383(9):825\u2013835. https:\/\/doi.org\/10.1056\/NEJMoa2005651","journal-title":"N Engl J Med"},{"issue":"9","key":"4942_CR4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","volume":"383","author":"A Drilon","year":"2020","unstructured":"Drilon A, Oxnard GR, Tan DSW et al (2020) Selpercatinib in RET fusion\u2013positive non\u2013small-cell lung cancer. N Engl J Med 383(9):813\u2013824. https:\/\/doi.org\/10.1056\/NEJMoa2005653","journal-title":"N Engl J Med"},{"issue":"6","key":"4942_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.5582\/ddt.2024.01076","volume":"18","author":"W Suzuki","year":"2025","unstructured":"Suzuki W, Gando Y, Yasu T (2025) Determination of selpercatinib in human plasma by HPLC-UV. Drug Discov Ther 18(6):387\u2013390. https:\/\/doi.org\/10.5582\/ddt.2024.01076","journal-title":"Drug Discov Ther"},{"key":"4942_CR6","unstructured":"U.S. Food and Drug Administration. Retevmo (selpercatinib) prescribing information. (2025) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/213246s015s016,218160s005s006lbl.pdf Accessed 11 Feb 2026"},{"issue":"11","key":"4942_CR7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40265-020-01343-7","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A (2020) Selpercatinib: first approval. Drugs 80(11):1119\u20131124. https:\/\/doi.org\/10.1007\/s40265-020-01343-7","journal-title":"Drugs"},{"key":"4942_CR8","unstructured":"Eli Lilly Japan. Retevmo Interview Form (2024) [Internet]. Available from: https:\/\/medical.lilly.com\/jp\/answers\/144697 Accessed 11 Feb 2026"},{"issue":"12","key":"4942_CR9","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/oncolo\/oyae282","volume":"29","author":"LE Raez","year":"2024","unstructured":"Raez LE, Massey AC, Barker SS et al (2024) Long-term safety of selpercatinib for rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001. Oncologist 29(12):1068\u20131078. https:\/\/doi.org\/10.1093\/oncolo\/oyae282","journal-title":"Oncologist"},{"issue":"6","key":"4942_CR10","first-page":"669","volume":"49","author":"M Nishio","year":"2022","unstructured":"Nishio M, Ohe Y, Ohashi K et al (2022) Efficacy and safety analysis of selpercatinib in patients with RET fusion-positive non-small cell lung cancer. Gan Kagaku Ryoho 49(6):669\u2013675","journal-title":"Gan Kagaku Ryoho"},{"issue":"6","key":"4942_CR11","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10637-025-01593-w","volume":"43","author":"Y Mihashi","year":"2025","unstructured":"Mihashi Y, Komuta K, Tsukaguchi A et al (2025) Multicenter retrospective study of selpercatinib treatment in Japan. Invest New Drugs 43(6):1201\u20131210. https:\/\/doi.org\/10.1007\/s10637-025-01593-w","journal-title":"Invest New Drugs"},{"issue":"6","key":"4942_CR12","doi-asserted-by":"publisher","first-page":"e86275","DOI":"10.7759\/cureus.86275","volume":"17","author":"T Shiraishi","year":"2025","unstructured":"Shiraishi T, Isoshima Y, Tahara M et al (2025) Pericardial effusion associated with selpercatinib. Cureus 17(6):e86275. https:\/\/doi.org\/10.7759\/cureus.86275","journal-title":"Cureus"},{"issue":"1","key":"4942_CR13","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1186\/s12885-024-13250-1","volume":"24","author":"J Qian","year":"2024","unstructured":"Qian J, Zhang S, Jiang C (2024) Adverse event profiles of selpercatinib: FAERS database analysis. BMC Cancer 24(1):1486. https:\/\/doi.org\/10.1186\/s12885-024-13250-1","journal-title":"BMC Cancer"},{"issue":"24","key":"4942_CR14","doi-asserted-by":"publisher","first-page":"9420","DOI":"10.3390\/ijms21249420","volume":"21","author":"JI Fortea","year":"2020","unstructured":"Fortea JI, Zipprich A, Fernandez-Mena C et al (2020) Congestive hepatopathy. Int J Mol Sci 21(24):9420. https:\/\/doi.org\/10.3390\/ijms21249420","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4942_CR15","doi-asserted-by":"publisher","first-page":"e58766","DOI":"10.7759\/cureus.58766","volume":"16","author":"R Haddadin","year":"2024","unstructured":"Haddadin R, Aboujaoude C, Trad G (2024) Congestive hepatopathy: a review of the literature. Cureus 16(4):e58766. https:\/\/doi.org\/10.7759\/cureus.58766","journal-title":"Cureus"},{"issue":"Suppl 1","key":"4942_CR16","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/S0168-8278(12)60004-X","volume":"56","author":"A Plessier","year":"2012","unstructured":"Plessier A, Rautou PE, Valla DC (2012) Management of hepatic vascular diseases. J Hepatol 56(Suppl 1):S25\u2013S38. https:\/\/doi.org\/10.1016\/S0168-8278(12)60004-X","journal-title":"J Hepatol"},{"issue":"13","key":"4942_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2165\/00003088-200443130-00003","volume":"43","author":"ID Cockshott","year":"2004","unstructured":"Cockshott ID (2004) Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 43(13):855\u2013878. https:\/\/doi.org\/10.2165\/00003088-200443130-00003","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"4942_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jcph.2409","volume":"64","author":"N Kassir","year":"2024","unstructured":"Kassir N, McDougall D, Kuruvilla D et al (2024) Exposure\u2013response relationships for pralsetinib. J Clin Pharmacol 64(6):685\u2013696. https:\/\/doi.org\/10.1002\/jcph.2409","journal-title":"J Clin Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04942-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04942-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04942-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:27:22Z","timestamp":1786937242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04942-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4942"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04942-5","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"93"}}